<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ethylphenidate - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/stimulants/">Stimulants</a> ‚Üí <span>Ethylphenidate</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>‚ö° Ethylphenidate</h1>
        <h2 class="chemical-name">Ethyl 2-phenyl-2-(piperidin-2-yl)acetate</h2>
         <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Ethylphenidate" 
                data-category="Stimulants" 
                data-chemical="Ethyl 2-phenyl-2-(piperidin-2-yl)acetate">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Common Names</h4>
              <span>Ethylphenidate</span> ‚Ä¢ <span>EPH</span> ‚Ä¢ <span>ET</span> ‚Ä¢ <span>Ethyl-MPH</span>
            </div>
            <div class="name-category">
              <h4>Research Names</h4>
              <span>EPH</span> ‚Ä¢ <span>Ethyl-phenidate</span> ‚Ä¢ <span>Ethylphenidate HCl</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Legal Ritalin</span> ‚Ä¢ <span>Study Drug</span> ‚Ä¢ <span>Focus Pills</span>
            </div>
            <div class="name-category">
              <h4>Chemical Names</h4>
              <span>Ethyl methylphenidate</span> ‚Ä¢ <span>RP-19819</span> ‚Ä¢ <span>EPD</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category stimulant">Stimulant</span>
          <span class="legal-status gray-area">Gray Area</span>
          <span class="duration long">4-8 hours</span>
          <span class="research-chemical">Research Chemical</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/ethylphenidate.jpg" alt="Ethylphenidate powder and molecular structure" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇÑH‚ÇÅ‚ÇâNO‚ÇÇ</p>
            <p>MW: 233.31 g/mol</p>
            <p>‚ö†Ô∏è RESEARCH CHEMICAL</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure Ethylphenidate (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder</li>
            <li><strong>Texture:</strong> Fine, fluffy powder or small crystals</li>
            <li><strong>Odor:</strong> Faint chemical odor, sometimes fishy</li>
            <li><strong>Taste:</strong> Bitter, numbing to tongue and nasal passages</li>
            <li><strong>Solubility:</strong> Highly soluble in water, ethanol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Available Forms</h4>
          <ul>
            <li><strong>Powder:</strong> Most common form, usually white crystalline</li>
            <li><strong>Capsules:</strong> Pre-measured doses in gelatin capsules</li>
            <li><strong>Pressed Tablets:</strong> Less common, often unmarked</li>
            <li><strong>Solution:</strong> Dissolved in propylene glycol for volumetric dosing</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Common Adulterants & Confusion</h4>
          <p><strong>Confusion with:</strong> Methylphenidate, 3,4-CTMP, 4F-MPH, isopropylphenidate</p>
          <p><strong>Adulterants:</strong> Caffeine, inositol, mannitol, lactose</p>
          <p><strong>Dangerous mixtures:</strong> Sometimes sold mixed with other phenidate analogs</p>
          <p><strong>Critical:</strong> Often mislabeled or confused with other research stimulants</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">2-5mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">5-15mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">15-30mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">30-50mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">50mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Route-Specific Dosing</h4>
        <ul>
          <li><strong>Oral:</strong> 15-40mg (longer onset, smoother experience)</li>
          <li><strong>Insufflation:</strong> 5-20mg (faster onset, shorter duration, harsh on nose)</li>
          <li><strong>Sublingual:</strong> 10-25mg (moderate onset, good bioavailability)</li>
          <li><strong>Rectal:</strong> 10-30mg (efficient absorption, longer duration)</li>
          <li><strong>Avoid IV/IM:</strong> High risk of complications, not recommended</li>
        </ul>
      </div>

      <div class="dosage-considerations">
        <h4>Important Considerations</h4>
        <ul>
          <li><strong>Redosing danger:</strong> Compulsive redosing common, increases cardiac risk</li>
          <li><strong>Tolerance builds fast:</strong> Efficacy decreases with frequent use</li>
          <li><strong>Individual variation:</strong> Response varies significantly between users</li>
          <li><strong>Cross-tolerance:</strong> With methylphenidate and other stimulants</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Research Chemical Warning:</strong> Limited human safety data. Start with lowest possible doses and test substance purity. Effects and dosing may vary between batches/suppliers.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Oral)</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-1:00</span>
          <span class="effect">Onset - alertness, focus increase</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:00-4:00</span>
          <span class="effect">Peak - intense focus, euphoria, energy</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-8:00</span>
          <span class="effect">Plateau - sustained concentration, reduced appetite</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00-24:00</span>
          <span class="effect">Comedown - fatigue, possible depression</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Positive Effects</h4>
          <ul>
            <li>Enhanced focus and concentration</li>
            <li>Increased motivation and productivity</li>
            <li>Mild to moderate euphoria</li>
            <li>Enhanced cognitive performance</li>
            <li>Increased energy and alertness</li>
            <li>Improved task persistence</li>
            <li>Enhanced working memory</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Negative Effects</h4>
          <ul>
            <li>Increased heart rate and blood pressure</li>
            <li>Appetite suppression</li>
            <li>Insomnia and sleep disruption</li>
            <li>Anxiety and jitteriness</li>
            <li>Compulsive behavior and redosing</li>
            <li>Irritability during comedown</li>
            <li>Nasal damage (if insufflated)</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Ethylphenidate is a dopamine and norepinephrine reuptake inhibitor (DNRI), functioning similarly to methylphenidate but with modified pharmacokinetics. It blocks DAT and NET transporters, preventing the reuptake of dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in synaptic clefts, particularly in prefrontal cortex and reward pathways.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>DAT (Dopamine transporter)</strong></span>
            <span class="affinity">High affinity (IC50: ~20 nM)</span>
            <span class="function">Primary euphoric and reward effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NET (Norepinephrine transporter)</strong></span>
            <span class="affinity">High affinity (IC50: ~35 nM)</span>
            <span class="function">Alertness, focus, cardiovascular effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>SERT (Serotonin transporter)</strong></span>
            <span class="affinity">Very weak (IC50: >10,000 nM)</span>
            <span class="function">Minimal direct serotonergic effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>VMAT2</strong></span>
            <span class="affinity">No significant activity</span>
            <span class="function">No vesicular monoamine transport effects</span>
          </div>
        </div>

        <h4>Pharmacokinetic Differences from Methylphenidate</h4>
        <div class="metabolism-details">
          <p><strong>Duration:</strong> Longer-acting than methylphenidate (4-8 hours vs 2-4 hours)</p>
          <p><strong>Metabolism:</strong> Slower hepatic metabolism, primarily by carboxylesterase</p>
          <p><strong>Active metabolites:</strong> Minimal active metabolite formation</p>
          <p><strong>Bioavailability:</strong> High oral bioavailability (~70-80%)</p>
          <p><strong>Half-life:</strong> Approximately 4-6 hours (vs 2-3 hours for methylphenidate)</p>
          <p><strong>Peak plasma:</strong> 1-2 hours after oral administration</p>
        </div>

        <h4>Neurochemical Effects</h4>
        <div class="neurochemical-effects">
          <p><strong>Dopamine increase:</strong> Primarily in nucleus accumbens and prefrontal cortex</p>
          <p><strong>Norepinephrine increase:</strong> Throughout cortex and sympathetic nervous system</p>
          <p><strong>Cognitive enhancement:</strong> Via prefrontal dopamine and norepinephrine modulation</p>
          <p><strong>Reward pathway:</strong> Activation of mesolimbic dopamine system</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Longer duration:</strong> Extended action compared to methylphenidate</li>
          <li><strong>Cocaine-like binding:</strong> Similar binding profile to cocaine but different kinetics</li>
          <li><strong>Abuse potential:</strong> High due to dopaminergic activity and euphoric effects</li>
          <li><strong>Tolerance development:</strong> Rapid tolerance to euphoric effects</li>
          <li><strong>Withdrawal syndrome:</strong> Dysphoria, fatigue, increased appetite after cessation</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Cardiovascular stress:</strong> Significant increases in heart rate and blood pressure</li>
            <li><strong>Research chemical:</strong> Limited long-term safety data in humans</li>
            <li><strong>Compulsive redosing:</strong> High potential for binge use</li>
            <li><strong>Sleep disruption:</strong> Can cause severe insomnia lasting days</li>
            <li><strong>Cardiac sensitization:</strong> May increase sensitivity to other stimulants</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Harm Reduction</h4>
          <ul>
            <li>Start with very low doses (2-5mg) to assess sensitivity</li>
            <li>Avoid frequent use - limit to once weekly maximum</li>
            <li>Monitor heart rate and blood pressure if possible</li>
            <li>Stay hydrated but avoid excessive water intake</li>
            <li>Plan for sleep disruption - avoid late dosing</li>
            <li>Have benzos available for comedown anxiety</li>
            <li>Use nasal saline rinse if insufflating</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Heart conditions, high blood pressure, hyperthyroidism, anxiety disorders, eating disorders, glaucoma, or history of stimulant abuse. Avoid during pregnancy/breastfeeding.</p>
      </div>

      <div class="research-chemical-warning">
        <h4>‚öóÔ∏è Research Chemical Risks</h4>
        <p><strong>Unknown long-term effects:</strong> No studies on chronic use in humans. Potential for unknown toxicity, drug interactions, or adverse effects. Quality and purity may vary between suppliers.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous</h4>
          <ul>
            <li><strong>MAOIs:</strong> Risk of hypertensive crisis, potentially fatal</li>
            <li><strong>Stimulants:</strong> Cocaine, amphetamines - extreme cardiovascular stress</li>
            <li><strong>Tramadol:</strong> Increased seizure risk, serotonin syndrome potential</li>
            <li><strong>Beta-blockers:</strong> Paradoxical hypertension, unopposed alpha effects</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High Risk</h4>
          <ul>
            <li><strong>Antidepressants:</strong> SSRIs/SNRIs may alter effects unpredictably</li>
            <li><strong>Blood pressure medications:</strong> May counteract therapeutic effects</li>
            <li><strong>Alcohol:</strong> Masks stimulant effects, increased cardiac stress</li>
            <li><strong>Caffeine:</strong> Additive stimulant effects, jitters, anxiety</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Caution</h4>
          <ul>
            <li><strong>Cannabis:</strong> May increase anxiety or paranoia during peak</li>
            <li><strong>Psychedelics:</strong> May intensify or alter psychedelic experiences</li>
            <li><strong>Benzodiazepines:</strong> May be needed for comedown but reduces stimulant effects</li>
            <li><strong>Antihistamines:</strong> May reduce stimulant effects</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Gray Area</strong> - Not federally scheduled, but may fall under Federal Analogue Act. Some states have banned it specifically.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Class B</strong> - Controlled under Psychoactive Substances Act 2016. Illegal to produce, supply, or possess.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá≥üá± Netherlands</h4>
            <p><strong>Banned</strong> - Specifically scheduled and illegal to manufacture or distribute.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá©üá™ Germany</h4>
            <p><strong>Banned</strong> - Controlled under BtMG (Narcotics Law) since 2014.</p>
          </div>
        </div>
        
        <div class="analog-act-warning">
          <h4>‚öñÔ∏è Analog Act Considerations</h4>
          <p>In jurisdictions with analog laws, ethylphenidate may be considered an analog of methylphenidate (Schedule II in US), making it potentially illegal for human consumption even when not explicitly scheduled.</p>
        </div>

        <div class="research-legal-status">
          <h4>üî¨ Research Status</h4>
          <p>Often sold as "research chemical" or "not for human consumption" to circumvent regulations. This does not make it legal for human use in many jurisdictions.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Development</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1944</span>
          <p>First synthesized as part of methylphenidate research by Ciba</p>
        </div>
        <div class="history-event">
          <span class="year">1960s-1990s</span>
          <p>Studied alongside methylphenidate for ADHD treatment potential</p>
        </div>
        <div class="history-event">
          <span class="year">2010</span>
          <p>Emerges in research chemical markets as "legal" methylphenidate alternative</p>
        </div>
        <div class="history-event">
          <span class="year">2011-2013</span>
          <p>Rapid rise in recreational use and research chemical vendor sales</p>
        </div>
        <div class="history-event">
          <span class="year">2014</span>
          <p>Germany becomes first major country to ban ethylphenidate</p>
        </div>
        <div class="history-event">
          <span class="year">2016</span>
          <p>UK bans under blanket Psychoactive Substances Act</p>
        </div>
        <div class="history-event">
          <span class="year">2018-present</span>
          <p>Increasing restrictions worldwide, decline in availability</p>
        </div>
      </div>

      <div class="research-chemical-context">
        <h4>Research Chemical Era</h4>
        <p>Ethylphenidate represents the "golden era" of research chemicals (2010-2016) when novel psychoactive substances were easily available online. Its popularity stemmed from being a "legal" version of Ritalin with similar effects but longer duration.</p>
        
        <h4>Academic Interest</h4>
        <p>Despite recreational use, ethylphenidate has legitimate research applications for studying dopamine reuptake inhibition and ADHD treatment mechanisms. Its longer duration made it interesting for pharmaceutical development.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research & Studies</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>ADHD Treatment Research</h4>
          <p>Limited studies comparing ethylphenidate to methylphenidate for ADHD treatment. Longer duration could offer advantages for once-daily dosing, but safety profile needs more study.</p>
        </div>
        
        <div class="research-item">
          <h4>Abuse Potential Studies</h4>
          <p>Research indicates high abuse potential similar to cocaine due to DAT binding profile. Studies show rapid tolerance development and withdrawal symptoms.</p>
        </div>
        
        <div class="research-item">
          <h4>Pharmacokinetic Research</h4>
          <p>Studies on metabolism and duration differences from methylphenidate. Research shows slower clearance and longer half-life contributing to extended effects.</p>
        </div>
        
        <div class="research-item">
          <h4>Cardiovascular Safety</h4>
          <p>Limited data on cardiovascular effects. Case reports suggest significant increases in heart rate and blood pressure, similar to other stimulants.</p>
        </div>
      </div>

      <div class="research-gaps">
        <h4>üö® Research Gaps</h4>
        <p><strong>Long-term effects:</strong> No studies on chronic use effects, neurotoxicity potential, or long-term cognitive impacts. Most safety data extrapolated from methylphenidate studies.</p>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Research & Information</h4>
        <ul>
          <li><a href="https://psychonautwiki.org/">PsychonautWiki</a> - User experiences and harm reduction</li>
          <li><a href="https://erowid.org/">Erowid</a> - Experience reports and information</li>
          <li><a href="https://pubmed.ncbi.nlm.nih.gov/">PubMed</a> - Scientific literature</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Testing & Harm Reduction</h4>
        <ul>
          <li><a href="https://drugsdata.org/">DrugsData.org</a> - Lab testing service</li>
          <li><a href="https://dancesafe.org/">DanceSafe</a> - Test kits and harm reduction</li>
          <li><a href="https://bluelight.org/">Bluelight</a> - Research chemical forum</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Education</h4>
        <ul>
          <li><a href="https://reddit.com/r/researchchemicals">/r/researchchemicals</a> - Community discussion</li>
          <li><a href="https://reddit.com/r/stims">/r/stims</a> - Stimulant harm reduction</li>
          <li><strong>Crisis Lines:</strong> Contact local emergency services for overdose</li>
        </ul>
      </div>
    </div>
  </div>

  <div class="research-chemical-disclaimer">
    <h3>‚öïÔ∏è Research Chemical Disclaimer</h3>
    <p><strong>LIMITED SAFETY DATA:</strong> Ethylphenidate has very limited human safety data. Long-term effects, toxicity potential, and drug interactions are poorly understood. This substance should be considered experimental with unknown risks. Quality and purity vary significantly between suppliers. Start with extremely low doses and avoid regular use.</p>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
</body>
</html>